Talactoferrin alfa

DRUG2 trials

Sponsors

Agennix

Conditions

Severe Sepsis

Phase 2

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

CompletedNCT00630656

AgennixSevere Sepsis

Start: 2008-04-30End: 2010-02-28Updated: 2011-08-23

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

SuspendedNCT01273779

AgennixSevere Sepsis

Start: 2011-06-30End: 2014-12-31Target: 1280Updated: 2012-02-03